WAVE Life Sciences Ltd (fra:1U5) Share Price

Company Profile

Business description
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington’s disease.
Contact
7 Straits View No. 12-00
Marina One East Tower
Singapore018936
SGP
T: +65 62363388
E: [email protected]
https://www.wavelifesciences.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
288

Recommended

We doubt the $5 billion is meaningful enough to force Nvidia to use Intel, either for core products or even for the chips in collaboration.

Brian Colello, CPA | 19 September 2025

Our Fair Value estimate once again reflects the stand-alone business and its growth potential.

Mark Taylor | 19 September 2025

Coverage of ASX listed REIT as investor interest in property continues to grow.

Yingqi Tan, CFA | 19 September 2025

Index	Last price	Change	% Change
All Ordinaries	9,088.50	34.00	-0.37%
CAC 40	7,854.61	36.39	0.47%
DAX 40	23,674.53	315.35	1.35%
Dow JONES (US)	46,142.42	124.10	0.27%
FTSE 100	9,228.11	32.45	0.35%
HKSE	26,548.27	109.76	0.42%
NASDAQ	22,470.72	209.40	0.94%
Nikkei 225	45,652.08	749.81	1.67%
NZX 50 Index	13,222.12	12.77	-0.10%
S&P 500	6,631.96	31.61	0.48%
S&P/ASX 200	8,800.00	48.50	-0.55%
SSE Composite Index	3,822.12	9.54	-0.25%